leisure time -WSS

leisure time

author：entertainment 2025-09-28 18:47:43 - browse：74

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： 'Essentially witchcraft:' A former naturopath takes on the field

WSS

STAT Virtual Event: ASCO Recap, Live!

Gilgo Beach: Police identify another victim in serial killing investigation

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Biden calls for immediate release of Niger's president amid apparent coup

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Stephen Quake on the Chan Zuckerberg quest to conquer disease

hotspot

leisure time

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Statins may not be needed by millions of people, study suggests

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

OTC birth control: A brief history of over the counter pill design

Supreme Court strikes down use of affirmative action

Study: Why relieving medical debt did not improve financial outcomes

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Gilgo Beach: Police identify another victim in serial killing investigation

New air purifier tech could be key to improving indoor air quality

'Ancient DNA,' 23andMe reveal African American ancestries

knowledge

Health care court cases: Humana, Sutter, Novant

Attacks on the drug industry will lead to fewer breakthroughs

ER docs worry over extreme heat as a 'mass casualty event'

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Cigna wins case to block Amy Bricker's move to CVS

White House drug shortage group privately met with industry

entertainment

knowledge

hotspot

knowledge